93 related articles for article (PubMed ID: 38597154)
21. Standard and controversies in sentinel node in breast cancer patients.
Veronesi P; Corso G
Breast; 2019 Nov; 48 Suppl 1():S53-S56. PubMed ID: 31839161
[TBL] [Abstract][Full Text] [Related]
22. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
[TBL] [Abstract][Full Text] [Related]
23. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
[TBL] [Abstract][Full Text] [Related]
24. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
Andersson Y; Bergkvist L; Frisell J; de Boniface J
Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
[TBL] [Abstract][Full Text] [Related]
25. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
26. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
[TBL] [Abstract][Full Text] [Related]
27. Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.
Gentilini OD; Botteri E; Sangalli C; Galimberti V; Porpiglia M; Agresti R; Luini A; Viale G; Cassano E; Peradze N; Toesca A; Massari G; Sacchini V; Munzone E; Leonardi MC; Cattadori F; Di Micco R; Esposito E; Sgarella A; Cattaneo S; Busani M; Dessena M; Bianchi A; Cretella E; Ripoll Orts F; Mueller M; Tinterri C; Chahuan Manzur BJ; Benedetto C; Veronesi P;
JAMA Oncol; 2023 Nov; 9(11):1557-1564. PubMed ID: 37733364
[TBL] [Abstract][Full Text] [Related]
28. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
[TBL] [Abstract][Full Text] [Related]
29. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection.
Zaveri S; Everidge S; FitzSullivan E; Hwang R; Smith BD; Lin H; Shen Y; Lucci A; Teshome M; Sun SX; Hunt KK; Kuerer HM
Ann Surg Oncol; 2023 Nov; 30(12):7015-7025. PubMed ID: 37458948
[TBL] [Abstract][Full Text] [Related]
30. Trends of Axillary Treatment in Sentinel Node-Positive Breast Cancer Patients Undergoing Mastectomy.
Verreck EEF; van Steenhoven JEC; Kuijer A; van Maaren MC; Simons JM; Siesling S; van Dalen T
Ann Surg Oncol; 2023 Sep; 30(9):5623-5632. PubMed ID: 37225832
[TBL] [Abstract][Full Text] [Related]
31. The Association Between Surgical Axillary Staging, Adjuvant Treatment Use and Survival in Older Women with Early Stage Breast Cancer: A Population-Based Study.
Castelo M; Sutradhar R; Faught N; Mata DGMM; Hahn E; Nguyen L; Paszat L; Rodin D; Trebinjac S; Fong C; Rakovitch E
Ann Surg Oncol; 2023 Jul; 30(7):3901-3912. PubMed ID: 36917335
[TBL] [Abstract][Full Text] [Related]
32. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
Bartels SAL; Donker M; Poncet C; Sauvé N; Straver ME; van de Velde CJH; Mansel RE; Blanken C; Orzalesi L; Klinkenbijl JHG; van der Mijle HCJ; Nieuwenhuijzen GAP; Veltkamp SC; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JWS; Belkacemi Y; Petignat P; Schinagl DAX; Coens C; van Tienhoven G; van Duijnhoven F; Rutgers EJT
J Clin Oncol; 2023 Apr; 41(12):2159-2165. PubMed ID: 36383926
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of the PORTRET tool to predict recurrence, overall survival, and other-cause mortality in older patients with breast cancer in the Netherlands: a population-based study.
van der Plas-Krijgsman WG; Giardiello D; Putter H; Steyerberg EW; Bastiaannet E; Stiggelbout AM; Mooijaart SP; Kroep JR; Portielje JEA; Liefers GJ; de Glas NA
Lancet Healthy Longev; 2021 Nov; 2(11):e704-e711. PubMed ID: 36098027
[TBL] [Abstract][Full Text] [Related]
34. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1-2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial.
Tinterri C; Gentile D; Gatzemeier W; Sagona A; Barbieri E; Testori A; Errico V; Bottini A; Marrazzo E; Dani C; Dozin B; Boni L; Bruzzi P; Fernandes B; Franceschini D; Spoto R; Torrisi R; Scorsetti M; Santoro A; Canavese G;
Ann Surg Oncol; 2022 Sep; 29(9):5732-5744. PubMed ID: 35552930
[TBL] [Abstract][Full Text] [Related]
35. Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial.
Appelgren M; Sackey H; Wengström Y; Johansson K; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Rydén L; Sund M; Alkner S; Vrou Offersen B; Filtenborg Tvedskov T; Christiansen P; de Boniface J;
Breast; 2022 Jun; 63():16-23. PubMed ID: 35279508
[TBL] [Abstract][Full Text] [Related]
36. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial.
Jung JG; Ahn SH; Lee S; Kim EK; Ryu JM; Park S; Lim W; Jung YS; Chung IY; Jeong J; Chang JH; Shin KH; Chang JM; Moon WK; Han W
BMC Cancer; 2022 Feb; 22(1):189. PubMed ID: 35184724
[TBL] [Abstract][Full Text] [Related]
37. POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes.
Goyal A; Mann GB; Fallowfield L; Duley L; Reed M; Dodwell D; Coleman RE; Fakis A; Newcombe R; Jenkins V; Whitham D; Childs M; Whynes D; Keeley V; Ellis I; Fairbrother P; Sadiq S; Monson K; Montgomery A; Tan W; Vale L; Homer T; Badger H; Haines RH; Lewis M; Megias D; Nabi Z; Singh P; Caraman A; Miles E;
BMJ Open; 2021 Dec; 11(12):e054365. PubMed ID: 34857578
[TBL] [Abstract][Full Text] [Related]
38. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
39. The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.
de Boniface J; Ahlgren J; Andersson Y; Bergkvist L; Frisell J; Lundstedt D; Olofsson Bagge R; Rydén L; Sund M;
Breast Cancer Res Treat; 2020 Feb; 180(1):167-176. PubMed ID: 31989379
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
